{"id":"https://openalex.org/W2004681966","doi":"https://doi.org/10.1007/s12325-008-0141-8","title":"Cost-effectiveness analysis of lopinavir/ritonavir and atazanavir+ritonavir regimens in the CASTLE study","display_name":"Cost-effectiveness analysis of lopinavir/ritonavir and atazanavir+ritonavir regimens in the CASTLE study","publication_year":2009,"publication_date":"2009-02-01","ids":{"openalex":"https://openalex.org/W2004681966","doi":"https://doi.org/10.1007/s12325-008-0141-8","mag":"2004681966","pmid":"https://pubmed.ncbi.nlm.nih.gov/19219410"},"language":"en","primary_location":{"id":"doi:10.1007/s12325-008-0141-8","doi":"https://doi.org/10.1007/s12325-008-0141-8","is_oa":false,"landing_page_url":"https://doi.org/10.1007/s12325-008-0141-8","pdf_url":null,"source":{"id":"https://openalex.org/S27230875","display_name":"Advances in Therapy","issn_l":"0741-238X","issn":["0741-238X","1865-8652"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-b","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-70","russia-white-list-2","vabb-shw"],"host_organization":"https://openalex.org/P4310320330","host_organization_name":"Adis, Springer Healthcare","host_organization_lineage":["https://openalex.org/P4310320330","https://openalex.org/P4310319965"],"host_organization_lineage_names":["Adis, Springer Healthcare","Springer Nature"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Advances in Therapy","raw_type":"journal-article"},"volume":null,"type":"article","indexed_in":["crossref","pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5043515095","display_name":"Kit N. Simpson","orcid":"https://orcid.org/0000-0002-1713-0632","observed_orcids":["https://orcid.org/0000-0002-1713-0632"]},"institutions":[{"id":"https://openalex.org/I153297377","display_name":"Medical University of South Carolina","ror":"https://ror.org/012jban78","country_code":"US","type":"education","lineage":["https://openalex.org/I153297377"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"Kit N. Simpson","raw_affiliation_strings":["Medical University of South Carolina, 151 B Rutledge Avenue, Room 409, Charleston, South Carolina 29425, USA. simpsonk@musc.edu","Medical University of South Carolina;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Medical University of South Carolina, 151 B Rutledge Avenue, Room 409, Charleston, South Carolina 29425, USA. simpsonk@musc.edu","institution_ids":["https://openalex.org/I153297377"]},{"raw_affiliation_string":"Medical University of South Carolina;","institution_ids":["https://openalex.org/I153297377"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5010066358","display_name":"Rukmini Rajagopalan","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210088555","display_name":"Abbott (United States)","ror":"https://ror.org/0052svj16","country_code":"US","type":"company","lineage":["https://openalex.org/I4210088555"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Rukmini Rajagopalan","raw_affiliation_strings":["Abbott Laboratories, Abbott Park, Illinois, USA","Abbott Laboratories"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Abbott Laboratories, Abbott Park, Illinois, USA","institution_ids":[]},{"raw_affiliation_string":"Abbott Laboratories","institution_ids":["https://openalex.org/I4210088555"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5113715360","display_name":"Birgitta Dietz","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210126753","display_name":"Abbott (Germany)","ror":"https://ror.org/02x2gk324","country_code":"DE","type":"company","lineage":["https://openalex.org/I4210088555","https://openalex.org/I4210126753"]}],"countries":["DE"],"is_corresponding":false,"raw_author_name":"Birgitta Dietz","raw_affiliation_strings":["Abbott GmbH & Co KG, Ludwigshafen, Germany","Abbott GmbH & Co KG"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Abbott GmbH & Co KG, Ludwigshafen, Germany","institution_ids":["https://openalex.org/I4210126753"]},{"raw_affiliation_string":"Abbott GmbH & Co KG","institution_ids":[]}]}],"institutions":[],"countries_distinct_count":2,"institutions_distinct_count":3,"corresponding_author_ids":["https://openalex.org/A5043515095"],"corresponding_institution_ids":["https://openalex.org/I153297377"],"apc_list":{"value":4790,"currency":"USD","value_usd":4790},"apc_paid":null,"fwci":5.9686,"has_fulltext":false,"cited_by_count":16,"citation_normalized_percentile":{"value":0.95759956,"is_in_top_1_percent":false,"is_in_top_10_percent":true},"cited_by_percentile_year":{"min":89,"max":98},"biblio":{"volume":"26","issue":"2","first_page":"185","last_page":"193"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10804","display_name":"Health Systems, Economic Evaluations, Quality of Life","score":0.8008000254631042,"subfield":{"id":"https://openalex.org/subfields/2002","display_name":"Economics and Econometrics"},"field":{"id":"https://openalex.org/fields/20","display_name":"Economics, Econometrics and Finance"},"domain":{"id":"https://openalex.org/domains/2","display_name":"Social Sciences"}},"topics":[{"id":"https://openalex.org/T10804","display_name":"Health Systems, Economic Evaluations, Quality of Life","score":0.8008000254631042,"subfield":{"id":"https://openalex.org/subfields/2002","display_name":"Economics and Econometrics"},"field":{"id":"https://openalex.org/fields/20","display_name":"Economics, Econometrics and Finance"},"domain":{"id":"https://openalex.org/domains/2","display_name":"Social Sciences"}},{"id":"https://openalex.org/T10526","display_name":"HIV/AIDS drug development and treatment","score":0.12039999663829803,"subfield":{"id":"https://openalex.org/subfields/2725","display_name":"Infectious Diseases"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10082","display_name":"HIV/AIDS Research and Interventions","score":0.029899999499320984,"subfield":{"id":"https://openalex.org/subfields/2725","display_name":"Infectious Diseases"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/lopinavir-ritonavir","display_name":"lopinavir/ritonavir","score":0.9929999709129333},{"id":"https://openalex.org/keywords/atazanavir-ritonavir","display_name":"atazanavir/ritonavir","score":0.9819999933242798},{"id":"https://openalex.org/keywords/hiv-antiretroviral-therapy","display_name":"HIV antiretroviral therapy","score":0.8840000033378601},{"id":"https://openalex.org/keywords/cost-effectiveness","display_name":"cost-effectiveness","score":0.8980000019073486},{"id":"https://openalex.org/keywords/budget-impact","display_name":"budget impact","score":0.8360000252723694},{"id":"https://openalex.org/keywords/coronary-heart-disease-risk","display_name":"coronary heart disease risk","score":0.9470000267028809},{"id":"https://openalex.org/keywords/hypercholesterolemia","display_name":"hypercholesterolemia","score":0.8960000276565552},{"id":"https://openalex.org/keywords/antiretroviral-naive-patients","display_name":"antiretroviral-naive patients","score":0.8679999709129333},{"id":"https://openalex.org/keywords/quality-adjusted-life-years","display_name":"quality-adjusted life years","score":0.8679999709129333},{"id":"https://openalex.org/keywords/markov-model","display_name":"Markov model","score":0.6729999780654907},{"id":"https://openalex.org/keywords/castle-studies","display_name":"castle studies","score":0.6349999904632568},{"id":"https://openalex.org/keywords/smokers","display_name":"smokers","score":0.5289999842643738},{"id":"https://openalex.org/keywords/cd4-count","display_name":"CD4 count","score":0.652999997138977}],"concepts":[{"id":"https://openalex.org/C2779298103","wikidata":"https://www.wikidata.org/wiki/Q422618","display_name":"Ritonavir","level":5,"score":0.9222436547279358},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.8957061171531677},{"id":"https://openalex.org/C2777182164","wikidata":"https://www.wikidata.org/wiki/Q422585","display_name":"Lopinavir","level":5,"score":0.876832902431488},{"id":"https://openalex.org/C2778414717","wikidata":"https://www.wikidata.org/wiki/Q423467","display_name":"Atazanavir","level":5,"score":0.8504596948623657},{"id":"https://openalex.org/C2781392899","wikidata":"https://www.wikidata.org/wiki/Q422618","display_name":"Lopinavir/ritonavir","level":5,"score":0.7333943843841553},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.4472726285457611},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.43415623903274536},{"id":"https://openalex.org/C159047783","wikidata":"https://www.wikidata.org/wiki/Q7215","display_name":"Virology","level":1,"score":0.4182698726654053},{"id":"https://openalex.org/C3013748606","wikidata":"https://www.wikidata.org/wiki/Q15787","display_name":"Human immunodeficiency virus (HIV)","level":2,"score":0.2862955331802368},{"id":"https://openalex.org/C142462285","wikidata":"https://www.wikidata.org/wiki/Q2528140","display_name":"Viral load","level":3,"score":0.2005361020565033},{"id":"https://openalex.org/C2993143319","wikidata":"https://www.wikidata.org/wiki/Q583050","display_name":"Antiretroviral therapy","level":4,"score":0.15588277578353882}],"mesh":[{"descriptor_ui":"D000069446","descriptor_name":"Atazanavir Sulfate","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D002017","descriptor_name":"Budgets","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D003327","descriptor_name":"Coronary Disease","qualifier_ui":"Q000150","qualifier_name":"complications","is_major_topic":false},{"descriptor_ui":"D003327","descriptor_name":"Coronary Disease","qualifier_ui":"Q000191","qualifier_name":"economics","is_major_topic":false},{"descriptor_ui":"D003327","descriptor_name":"Coronary Disease","qualifier_ui":"Q000453","qualifier_name":"epidemiology","is_major_topic":false},{"descriptor_ui":"D003362","descriptor_name":"Cost-Benefit Analysis","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D003661","descriptor_name":"Decision Support Techniques","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D004359","descriptor_name":"Drug Therapy, Combination","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008017","descriptor_name":"Life Expectancy","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008390","descriptor_name":"Markov Chains","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D009842","descriptor_name":"Oligopeptides","qualifier_ui":"Q000191","qualifier_name":"economics","is_major_topic":true},{"descriptor_ui":"D009842","descriptor_name":"Oligopeptides","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D011725","descriptor_name":"Pyridines","qualifier_ui":"Q000191","qualifier_name":"economics","is_major_topic":true},{"descriptor_ui":"D011725","descriptor_name":"Pyridines","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D011744","descriptor_name":"Pyrimidinones","qualifier_ui":"Q000191","qualifier_name":"economics","is_major_topic":true},{"descriptor_ui":"D011744","descriptor_name":"Pyrimidinones","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D012907","descriptor_name":"Smoking","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D012907","descriptor_name":"Smoking","qualifier_ui":"Q000191","qualifier_name":"economics","is_major_topic":false},{"descriptor_ui":"D014481","descriptor_name":"United States","qualifier_ui":"Q000453","qualifier_name":"epidemiology","is_major_topic":false},{"descriptor_ui":"D015658","descriptor_name":"HIV Infections","qualifier_ui":"Q000150","qualifier_name":"complications","is_major_topic":false},{"descriptor_ui":"D015658","descriptor_name":"HIV Infections","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D015658","descriptor_name":"HIV Infections","qualifier_ui":"Q000191","qualifier_name":"economics","is_major_topic":false},{"descriptor_ui":"D015658","descriptor_name":"HIV Infections","qualifier_ui":"Q000453","qualifier_name":"epidemiology","is_major_topic":false},{"descriptor_ui":"D016527","descriptor_name":"Drug Costs","qualifier_ui":"Q000706","qualifier_name":"statistics & numerical data","is_major_topic":false},{"descriptor_ui":"D017046","descriptor_name":"Cost Savings","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D017059","descriptor_name":"Models, Econometric","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D018791","descriptor_name":"CD4 Lymphocyte Count","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D019057","descriptor_name":"Quality-Adjusted Life Years","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D019380","descriptor_name":"Anti-HIV Agents","qualifier_ui":"Q000191","qualifier_name":"economics","is_major_topic":true},{"descriptor_ui":"D019380","descriptor_name":"Anti-HIV Agents","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D019438","descriptor_name":"Ritonavir","qualifier_ui":"Q000191","qualifier_name":"economics","is_major_topic":true},{"descriptor_ui":"D019438","descriptor_name":"Ritonavir","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D061466","descriptor_name":"Lopinavir","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false}],"locations_count":2,"locations":[{"id":"doi:10.1007/s12325-008-0141-8","doi":"https://doi.org/10.1007/s12325-008-0141-8","is_oa":false,"landing_page_url":"https://doi.org/10.1007/s12325-008-0141-8","pdf_url":null,"source":{"id":"https://openalex.org/S27230875","display_name":"Advances in Therapy","issn_l":"0741-238X","issn":["0741-238X","1865-8652"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-b","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-70","russia-white-list-2","vabb-shw"],"host_organization":"https://openalex.org/P4310320330","host_organization_name":"Adis, Springer Healthcare","host_organization_lineage":["https://openalex.org/P4310320330","https://openalex.org/P4310319965"],"host_organization_lineage_names":["Adis, Springer Healthcare","Springer Nature"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Advances in Therapy","raw_type":"journal-article"},{"id":"pmid:19219410","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/19219410","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Advances in therapy","raw_type":"Comparative Study"}],"best_oa_location":null,"sustainable_development_goals":[{"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3","score":1.0}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":13,"referenced_works":["https://openalex.org/W631714011","https://openalex.org/W1979178378","https://openalex.org/W1985662879","https://openalex.org/W1994222210","https://openalex.org/W2003479257","https://openalex.org/W2021028449","https://openalex.org/W2038002163","https://openalex.org/W2063994782","https://openalex.org/W2064303441","https://openalex.org/W2098131455","https://openalex.org/W2121894695","https://openalex.org/W2135857551","https://openalex.org/W2171236519"],"related_works":["https://openalex.org/W1978092999","https://openalex.org/W2062568251","https://openalex.org/W2080341658","https://openalex.org/W2114501704","https://openalex.org/W2135857551","https://openalex.org/W2167528679","https://openalex.org/W2085677441","https://openalex.org/W1974011017","https://openalex.org/W7098552010","https://openalex.org/W1983896142"],"abstract_inverted_index":null,"counts_by_year":[{"year":2014,"cited_by_count":5},{"year":2013,"cited_by_count":3},{"year":2012,"cited_by_count":1}],"updated_date":"2026-10-31T12:09:11.096373","created_date":"2016-06-24T00:00:00"}